Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.

[1]  J. Spertus,et al.  Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. , 2021, JAMA cardiology.

[2]  N. Brunetti,et al.  Eligibility of outpatients with chronic heart failure for sodium–glucose co‐transporter‐2 inhibitors , 2021, ESC heart failure.

[3]  G. Filippatos,et al.  Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial , 2021, European heart journal.

[4]  S. Solomon,et al.  Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. , 2020, JAMA cardiology.

[5]  A. Kansal,et al.  Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure , 2020, ESC heart failure.

[6]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[7]  G. Filippatos,et al.  SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.

[8]  J. McMurray,et al.  Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF , 2020, European journal of heart failure.

[9]  Akshay S. Desai,et al.  Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. , 2020, JACC. Heart failure.

[10]  G. Fonarow,et al.  Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure. , 2020, JAMA cardiology.

[11]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[12]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[13]  Nicola Orsini,et al.  Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. , 2018, JACC. Heart failure.

[14]  Roland A Matsouaka,et al.  Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. , 2017, Journal of the American College of Cardiology.

[15]  L. Lund,et al.  Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure , 2017, Circulation. Heart failure.

[16]  R. Starling,et al.  Patients Not Meeting PARADIGM-HF Enrollment Criteria Are Eligible for Sacubitril/Valsartan on the Basis of FDA Approval: The Need to Close the Gap. , 2017, JACC. Heart failure.

[17]  J. Cleland,et al.  What proportion of patients with chronic heart failure are eligible for sacubitril–valsartan? , 2017, European journal of heart failure.